GlaxoSmithKline plc (LON:GSK) has earned an average rating of “Hold” from the twenty-five analysts that are presently covering the stock. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and nine have given a buy rating to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is GBX 1,736.19 ($21.69).

Several brokerages have recently issued reports on GSK. Deutsche Bank AG restated a “hold” rating and issued a GBX 1,870 ($23.36) target price on shares of GlaxoSmithKline plc in a report on Wednesday, October 12th. Beaufort Securities restated a “buy” rating on shares of GlaxoSmithKline plc in a report on Tuesday, August 2nd. Jefferies Group raised their target price on shares of GlaxoSmithKline plc from GBX 1,900 ($23.74) to GBX 1,950 ($24.36) and gave the stock a “buy” rating in a report on Thursday, October 13th. BNP Paribas restated a “neutral” rating on shares of GlaxoSmithKline plc in a report on Friday, July 29th. Finally, Bryan, Garnier & Co restated a “buy” rating on shares of GlaxoSmithKline plc in a report on Thursday, July 28th.

GlaxoSmithKline plc (LON:GSK) opened at 1522.50 on Tuesday. The firm’s 50-day moving average is GBX 1,623.89 and its 200 day moving average is GBX 1,585.38. The firm’s market cap is GBX 74.08 billion. GlaxoSmithKline plc has a 12-month low of GBX 1,277.25 and a 12-month high of GBX 1,745.56.

The business also recently disclosed a dividend, which will be paid on Thursday, January 12th. Investors of record on Thursday, November 3rd will be paid a dividend of GBX 19 ($0.24) per share. The ex-dividend date is Thursday, November 3rd. This represents a dividend yield of 1.17%.

In related news, insider Sir Andrew P. Witty sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, October 27th. The stock was sold at an average price of GBX 1,636 ($20.44), for a total transaction of £163,600 ($204,397.80). Also, insider Manvinder Singh Banga acquired 1,750 shares of the business’s stock in a transaction that occurred on Wednesday, October 26th. The shares were bought at an average price of GBX 1,643 ($20.53) per share, with a total value of £28,752.50 ($35,922.66).

About GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.

Receive News & Stock Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related stocks with our FREE daily email newsletter.